Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Biosolution","sponsor":"Mundipharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mundipharma, Biosolution to market CartiLife in South Korea","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Biosolution

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.

            Lead Product(s): Chondrocytes

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Recipient: Mundipharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY